Critical Path Public Private Partnerships Clinical Trials Optional
The FDA seeks applications to maintain and manage existing research consortia established by the Critical Path Institute to foster drug innovation and development.
Funder: Food and Drug Administration
Due Dates: To be announced (forecasted opportunity)
Funding Amounts: $20,000,000 (single award; cooperative agreement)
Summary: Supports the continued management of consortia established by the Critical Path Institute to advance drug innovation, development, and regulatory science.
Key Information: Eligibility is limited to the Critical Path Institute; this is a renewal of a prior cooperative agreement.
Description
This funding opportunity from the Food and Drug Administration (FDA) is a forecasted cooperative agreement intended to support the ongoing maintenance and management of existing consortia groups convened and established by the Critical Path Institute. The award is part of the FDA's Critical Path Initiative, which aims to foster innovation in drug product development, accelerate the development and manufacturing of therapeutics, and enhance the safety, efficacy, quality, and performance of medical products.
The selected recipient will be responsible for developing and implementing innovative, collaborative projects in research, education, and outreach. These efforts are designed to advance regulatory science, promote drug innovation, and facilitate the translation of new therapies from research to clinical use.
This opportunity is a renewal of cooperative agreement #5U18FD005320 and is authorized under Section 566 of the Federal Food, Drug, and Cosmetic Act.
